University of Otago   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Dunedin New Zealand (1869)

Organization Overview

First Clinical Trial
2003
NCT00856336
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Christchurch Clinical Studies Trust | Christchurch Clinical Studies Trust Ltd | Christchurch Hospital | Christchurch Hospital, NZ | Christchurch Hospital NZ, New Zealand | Christchurch Women's Hospital | Department of Medicine, University of Otago | Oncology Service, Christchurch Hospital | Otago University | Otago University, New Zealand | University of Otago | University of Otago, Christchurch | Wellington Hospital, New Zealand

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 2)

Bacteremia (Phase 4)

Birth Weight (Phase 4)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Embolism (Phase 4)

Fibrosis (Phase 2)

Gout (Phase 2)

Hyperglycemia (Phase 4)

Idiopathic Pulmonary Fibrosis (Phase 2)

Infections (Phase 4)

Inflammatory Bowel Diseases (Phase 4)

Intestinal Diseases (Phase 4)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Pancreatitis (Phase 4)

Periodontal Diseases (Phase 3)

Periodontitis (Phase 3)

Psoriasis (Phase 1)

Pulmonary Embolism (Phase 4)

Pulmonary Fibrosis (Phase 2)

Renal Insufficiency (Phase 1)

Sclerosis (Phase 2)

Thrombosis (Phase 4)

Venous Thrombosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 22
  • # of Trial APIs: 26